| HORŇÁK, Tomáš, Lukáš SEMERÁD, Daniela ŽÁČKOVÁ, Barbora WEINBERGEROVÁ, Zuzana ŠUSTKOVÁ, Jiřina PROCHÁZKOVÁ, Petra BELOHLAVKOVA, Lukas STEJSKAL, Peter ROHON, Edgar FABER, Pavel ZAK, Jiří MAYER and Zdeněk RÁČIL. Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study. LEUKEMIA & LYMPHOMA. LONDON: TAYLOR & FRANCIS, 2020, vol. 61, No 2, p. 494-496. ISSN 1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2019.1672054. |
Other formats:
BibTeX
LaTeX
RIS
@article{1623156,
author = {Horňák, Tomáš and Semerád, Lukáš and Žáčková, Daniela and Weinbergerová, Barbora and Šustková, Zuzana and Procházková, Jiřina and Belohlavkova, Petra and Stejskal, Lukas and Rohon, Peter and Faber, Edgar and Zak, Pavel and Mayer, Jiří and Ráčil, Zdeněk},
article_location = {LONDON},
article_number = {2},
doi = {http://dx.doi.org/10.1080/10428194.2019.1672054},
keywords = {serum lipids; cardiovascular risk; nilotinib and imatinib therapy},
language = {eng},
issn = {1042-8194},
journal = {LEUKEMIA & LYMPHOMA},
title = {Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study},
url = {https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1672054},
volume = {61},
year = {2020}
}
TY - JOUR
ID - 1623156
AU - Horňák, Tomáš - Semerád, Lukáš - Žáčková, Daniela - Weinbergerová, Barbora - Šustková, Zuzana - Procházková, Jiřina - Belohlavkova, Petra - Stejskal, Lukas - Rohon, Peter - Faber, Edgar - Zak, Pavel - Mayer, Jiří - Ráčil, Zdeněk
PY - 2020
TI - Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study
JF - LEUKEMIA & LYMPHOMA
VL - 61
IS - 2
SP - 494-496
EP - 494-496
PB - TAYLOR & FRANCIS
SN - 10428194
KW - serum lipids
KW - cardiovascular risk
KW - nilotinib and imatinib therapy
UR - https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1672054
L2 - https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1672054
N2 - Tyrosine kinase inhibitors (TKI) have dramatically improved the prognosis of CML patients with life expectancy close to individuals without CML [1], and therefore the longterm safety of TKIs has become especially important due to the potential for lifelong treatment. Nilotinib (NILO) tends to have a negative effect on lipid [2] and glucose [3] metabolism, while imatinib (IMA) seems to improve [4] these abnormalities. Although the data appear convincing, the real impact of these changes on cardiovascular (CV) risk and the development of CV complications during TKI therapy have not yet been confirmed.
ER -
HORŇÁK, Tomáš, Lukáš SEMERÁD, Daniela ŽÁČKOVÁ, Barbora WEINBERGEROVÁ, Zuzana ŠUSTKOVÁ, Jiřina PROCHÁZKOVÁ, Petra BELOHLAVKOVA, Lukas STEJSKAL, Peter ROHON, Edgar FABER, Pavel ZAK, Jiří MAYER and Zdeněk RÁČIL. Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study. \textit{LEUKEMIA \&{} LYMPHOMA}. LONDON: TAYLOR \&{} FRANCIS, 2020, vol.~61, No~2, p.~494-496. ISSN~1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2019.1672054.
|
